Letters

Reply from Clozaril Patient Monitoring Service

BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7067.1262a (Published 16 November 1996) Cite this as: BMJ 1996;313:1262
  1. D P O'Sullivan,
  2. K P Lynch
  1. Head of pharmacovigilance Medical adviser in pharmacovigilance Sandoz Pharmaceuticals, Frimley, Camberley GU16 5SG

    EDITOR,—We have been aware for some time that the strict haematological limits used by the Clozaril Patient Monitoring Service may exclude patients who normally have low white cell counts from receiving clozapine. Lawton et al reported “normal neutropenia” in an Afro-Caribbean patient taking clozapine and expressed similar concerns to those raised by Nigel Fisher and Barbara Baigent.1 In answering Lawton et al we explained why the safety limits were set so strictly and provided data to support …

    View Full Text

    Sign in

    Log in through your institution

    Subscribe